PRMT5 and neoplasm: MTA-cooperative PRMT5 inhibitors have the ability to maintain potent anti-tumor activities, but avoid dose-limiting hematology toxicity in cancer patients harboring homozygous loss of MTAP as shown by MRTX1719 and AMG193’s clinical studies (64, 70).